定了!欧狄沃定价9260RMB(100mg),28日将在中国多城市开售

2018-08-20 肿瘤防治科普团队 美中嘉和

今日,中国首个上市PD-1药物(免疫治疗药物)——欧狄沃(Opdivo)也叫“O药”,定价出炉:O药定价40mg/10ml 价格:4591RMB100mg/10ml 价格:9260RMB8月28日起,将在中国多城市开售用法用量举例:3mg/kg,每两周静脉注射一次。以60Kg为例,一次需使用1支100mg/10ml和2支40mg/10ml,共18442元每两周,一个月共36884元。(同样情况香港

今日,中国首个上市PD-1药物(免疫治疗药物)——欧狄沃(Opdivo)也叫“O药”,定价出炉:

O药定价

40mg/10ml 价格:4591RMB

100mg/10ml 价格:9260RMB

8月28日起,将在中国多城市开售

用法用量举例:3mg/kg,每两周静脉注射一次。以60Kg为例,一次需使用1支100mg/10ml和2支40mg/10ml,共18442元每两周,一个月共36884元。(同样情况香港价格为58868元,约比香港便宜2.2万,一年可为患者节约超过24万)


温馨提示:以上建议零售价跟实际价格会有差异,以患者购药店为准。

2018年6月15日,欧狄沃(Opdivo),也叫纳武利尤单抗注射液(Nivolumab Injection),人们常常称为“O药”,获得中国国家药品监督管理局批准,成为中国大陆地区第一个获批上市的肿瘤免疫治疗药物。

无数人欢呼:“中国癌症治疗终于迎来的‘免疫治疗’时代”,可大家激动地并不“彻底”,因为谁也不知道“药品获批”与“患者知晓药品价格,且能买到手”之间,到底还有多长的路要走。

终于,欧狄沃定价今日出炉,且将在多个城市开售,这次,中国的患者也能在家门口买到PD-1药物了,这对很多肿瘤患者来说,真的是件值得高兴的事情!



中国上市欧狄沃(O药)的适应症

本次中国批准上市的“O药”仅用于非小细胞肺癌的二线治疗,具体来说,适用于治疗表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性、既往接受过含铂方案化疗后疾病进展或不可耐受的局部晚期或转移性非小细胞肺癌NSCLC)成人患者。

欧狄沃(O药)本领有几何?

1. 它能为肺癌患者带来更好的生存获益

一项中国患者为主的(90%为中国患者)III期临床试验CheckMate-078结果显示,相比于多西他赛化疗,“O药”可降低死亡风险32%,能够明显延长患者的总生存期(OS)、客观缓解率(ORR)、无进展生存期(PFS),不良反应也比多西他赛化疗更低[1]。

鳞癌和非鳞癌患者中均能获益

鳞癌和非鳞癌患者的死亡风险分别降低39% (HR 0.61[95% CI:0.42, 0.89])和24% (HR 0.76 [95% CI: 0.56, 1.04])。

吴一龙教授接受采访时表示:“中国人身上鳞癌效果显示特别好,目前在全世界鳞癌患者中表现最好。” [2]

不同PD-L1表达水平的患者均能获益

PD-L1表达≥1% 和<1%的患者,其死亡风险分别降低38% (HR 0.62 [95% CI: 0.45, 0.87])和25% (HR 0.75 [95% CI: 0.52, 1.09] )。

吴一龙教授在接受采访时表示:“二线治疗使用欧狄沃?不需检测PD-L1表达,都可以使用。” [2]

关于CheckMate-078试验详情,请阅读《中国首份PD-1治疗大数据公布,死亡风险下降32%》

2. 它值得更多类型肿瘤患者的期待

因为PD-1/PD-L1 药物的作用是广谱的,原则上来说,这类药物的适应症也绝不止一种。目前FDA(美国国家药品监督管理局)批准的“O药”适应证已达7种,包括:黑色素瘤、肾细胞癌、非小细胞肺癌、经典霍奇金淋巴瘤、尿路上皮癌、直肠癌以及肝癌。我们可以期待,它能为更多类型的中国肿瘤患者带来益处。

欧狄沃(O药)有没有慈善赠药计划?


赠药或医保政策还在谈判中,稍后公布:如果不能进入国家医保,将有赠药。所有符合条件的患者均可从用药第一天溯,提醒:留好购药发票等。

欧狄沃(O药)能不能进医保?什么时候进?

暂时没有答案,如今药品价格已定,接下来关于能够进医保的问题,应该也在讨论之列了。希望能等来好消息。对于PD-1的医保问题,或许,我们可以参考另外一个重磅靶向抗癌药——奥西替尼(AZD9291)的医保进程:

2017年3月底,奥西替尼获得国家批准,用于EGFR T790M突变的晚期肺癌患者。

2018年1月1日,奥西替尼纳入浙江省大病保险支付范围药品名单,切实为肿瘤患者带来益处。(《浙江省人力资源和社会保障厅关于将阿达木单抗等28种药品纳入大病保险支付范围的通知》)

O药获批后,K药、乳腺癌药物爱博新、肺癌药物阿来替尼也已经相继在中国获批,众多肿瘤患者也在翘首期盼能够早日知道这些新药的定价等购买信息。

一般来说,在药物获批2个月左右能够知道药物的购买信息,美中嘉和会持续关注,第一时间将最新消息推送给大家。

参考文献

[1]https://news.bms.com/press-release/corporatefinancial-news/opdivo-nivolumab-first-pd-1-inhibitor-demonstrate-superior-sur

[2]http://m.medlive.cn/cms/research/147602?_wx=1&info=eyJhY

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=348539, encodeId=dd6834853946, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=093a2086909, createdName=1321f36813m, createdTime=Mon Oct 08 21:43:20 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340493, encodeId=631e340493a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 24 07:51:50 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376928, encodeId=5cfe13e6928f6, content=<a href='/topic/show?id=4df06311110' target=_blank style='color:#2F92EE;'>#欧狄沃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63111, encryptionId=4df06311110, topicName=欧狄沃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Aug 22 06:37:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339773, encodeId=cb95339e73f5, content=得一个癌症拖累两家子人,用家庭的幸福换取癌症的最后生存期限,这样的政府还是不给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:55:27 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339772, encodeId=53d1339e7233, content=这么高的费用居然还好意思说, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:53:45 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339757, encodeId=1a6a339e574e, content=还是挺高的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon Aug 20 16:15:32 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339754, encodeId=413b339e54d7, content=什么时候有针对胃食管结合部腺癌的药物啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc742343280, createdName=12296478m17暂无昵称, createdTime=Mon Aug 20 16:11:51 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339753, encodeId=b1af339e53bc, content=一个月近四万 在中国又有多少人能用的起, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adc92365722, createdName=122e0f42m02暂无昵称, createdTime=Mon Aug 20 16:06:31 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2018-10-08 1321f36813m

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=348539, encodeId=dd6834853946, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=093a2086909, createdName=1321f36813m, createdTime=Mon Oct 08 21:43:20 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340493, encodeId=631e340493a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 24 07:51:50 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376928, encodeId=5cfe13e6928f6, content=<a href='/topic/show?id=4df06311110' target=_blank style='color:#2F92EE;'>#欧狄沃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63111, encryptionId=4df06311110, topicName=欧狄沃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Aug 22 06:37:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339773, encodeId=cb95339e73f5, content=得一个癌症拖累两家子人,用家庭的幸福换取癌症的最后生存期限,这样的政府还是不给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:55:27 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339772, encodeId=53d1339e7233, content=这么高的费用居然还好意思说, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:53:45 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339757, encodeId=1a6a339e574e, content=还是挺高的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon Aug 20 16:15:32 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339754, encodeId=413b339e54d7, content=什么时候有针对胃食管结合部腺癌的药物啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc742343280, createdName=12296478m17暂无昵称, createdTime=Mon Aug 20 16:11:51 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339753, encodeId=b1af339e53bc, content=一个月近四万 在中国又有多少人能用的起, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adc92365722, createdName=122e0f42m02暂无昵称, createdTime=Mon Aug 20 16:06:31 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2018-08-24 phoebeyan520

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=348539, encodeId=dd6834853946, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=093a2086909, createdName=1321f36813m, createdTime=Mon Oct 08 21:43:20 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340493, encodeId=631e340493a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 24 07:51:50 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376928, encodeId=5cfe13e6928f6, content=<a href='/topic/show?id=4df06311110' target=_blank style='color:#2F92EE;'>#欧狄沃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63111, encryptionId=4df06311110, topicName=欧狄沃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Aug 22 06:37:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339773, encodeId=cb95339e73f5, content=得一个癌症拖累两家子人,用家庭的幸福换取癌症的最后生存期限,这样的政府还是不给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:55:27 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339772, encodeId=53d1339e7233, content=这么高的费用居然还好意思说, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:53:45 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339757, encodeId=1a6a339e574e, content=还是挺高的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon Aug 20 16:15:32 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339754, encodeId=413b339e54d7, content=什么时候有针对胃食管结合部腺癌的药物啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc742343280, createdName=12296478m17暂无昵称, createdTime=Mon Aug 20 16:11:51 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339753, encodeId=b1af339e53bc, content=一个月近四万 在中国又有多少人能用的起, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adc92365722, createdName=122e0f42m02暂无昵称, createdTime=Mon Aug 20 16:06:31 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=348539, encodeId=dd6834853946, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=093a2086909, createdName=1321f36813m, createdTime=Mon Oct 08 21:43:20 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340493, encodeId=631e340493a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 24 07:51:50 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376928, encodeId=5cfe13e6928f6, content=<a href='/topic/show?id=4df06311110' target=_blank style='color:#2F92EE;'>#欧狄沃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63111, encryptionId=4df06311110, topicName=欧狄沃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Aug 22 06:37:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339773, encodeId=cb95339e73f5, content=得一个癌症拖累两家子人,用家庭的幸福换取癌症的最后生存期限,这样的政府还是不给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:55:27 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339772, encodeId=53d1339e7233, content=这么高的费用居然还好意思说, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:53:45 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339757, encodeId=1a6a339e574e, content=还是挺高的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon Aug 20 16:15:32 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339754, encodeId=413b339e54d7, content=什么时候有针对胃食管结合部腺癌的药物啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc742343280, createdName=12296478m17暂无昵称, createdTime=Mon Aug 20 16:11:51 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339753, encodeId=b1af339e53bc, content=一个月近四万 在中国又有多少人能用的起, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adc92365722, createdName=122e0f42m02暂无昵称, createdTime=Mon Aug 20 16:06:31 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2018-08-20 1331f12a6dm

    得一个癌症拖累两家子人,用家庭的幸福换取癌症的最后生存期限,这样的政府还是不给力

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=348539, encodeId=dd6834853946, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=093a2086909, createdName=1321f36813m, createdTime=Mon Oct 08 21:43:20 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340493, encodeId=631e340493a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 24 07:51:50 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376928, encodeId=5cfe13e6928f6, content=<a href='/topic/show?id=4df06311110' target=_blank style='color:#2F92EE;'>#欧狄沃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63111, encryptionId=4df06311110, topicName=欧狄沃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Aug 22 06:37:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339773, encodeId=cb95339e73f5, content=得一个癌症拖累两家子人,用家庭的幸福换取癌症的最后生存期限,这样的政府还是不给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:55:27 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339772, encodeId=53d1339e7233, content=这么高的费用居然还好意思说, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:53:45 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339757, encodeId=1a6a339e574e, content=还是挺高的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon Aug 20 16:15:32 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339754, encodeId=413b339e54d7, content=什么时候有针对胃食管结合部腺癌的药物啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc742343280, createdName=12296478m17暂无昵称, createdTime=Mon Aug 20 16:11:51 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339753, encodeId=b1af339e53bc, content=一个月近四万 在中国又有多少人能用的起, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adc92365722, createdName=122e0f42m02暂无昵称, createdTime=Mon Aug 20 16:06:31 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2018-08-20 1331f12a6dm

    这么高的费用居然还好意思说

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=348539, encodeId=dd6834853946, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=093a2086909, createdName=1321f36813m, createdTime=Mon Oct 08 21:43:20 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340493, encodeId=631e340493a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 24 07:51:50 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376928, encodeId=5cfe13e6928f6, content=<a href='/topic/show?id=4df06311110' target=_blank style='color:#2F92EE;'>#欧狄沃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63111, encryptionId=4df06311110, topicName=欧狄沃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Aug 22 06:37:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339773, encodeId=cb95339e73f5, content=得一个癌症拖累两家子人,用家庭的幸福换取癌症的最后生存期限,这样的政府还是不给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:55:27 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339772, encodeId=53d1339e7233, content=这么高的费用居然还好意思说, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:53:45 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339757, encodeId=1a6a339e574e, content=还是挺高的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon Aug 20 16:15:32 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339754, encodeId=413b339e54d7, content=什么时候有针对胃食管结合部腺癌的药物啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc742343280, createdName=12296478m17暂无昵称, createdTime=Mon Aug 20 16:11:51 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339753, encodeId=b1af339e53bc, content=一个月近四万 在中国又有多少人能用的起, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adc92365722, createdName=122e0f42m02暂无昵称, createdTime=Mon Aug 20 16:06:31 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2018-08-20 易水河

    还是挺高的啊

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=348539, encodeId=dd6834853946, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=093a2086909, createdName=1321f36813m, createdTime=Mon Oct 08 21:43:20 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340493, encodeId=631e340493a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 24 07:51:50 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376928, encodeId=5cfe13e6928f6, content=<a href='/topic/show?id=4df06311110' target=_blank style='color:#2F92EE;'>#欧狄沃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63111, encryptionId=4df06311110, topicName=欧狄沃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Aug 22 06:37:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339773, encodeId=cb95339e73f5, content=得一个癌症拖累两家子人,用家庭的幸福换取癌症的最后生存期限,这样的政府还是不给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:55:27 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339772, encodeId=53d1339e7233, content=这么高的费用居然还好意思说, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:53:45 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339757, encodeId=1a6a339e574e, content=还是挺高的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon Aug 20 16:15:32 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339754, encodeId=413b339e54d7, content=什么时候有针对胃食管结合部腺癌的药物啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc742343280, createdName=12296478m17暂无昵称, createdTime=Mon Aug 20 16:11:51 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339753, encodeId=b1af339e53bc, content=一个月近四万 在中国又有多少人能用的起, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adc92365722, createdName=122e0f42m02暂无昵称, createdTime=Mon Aug 20 16:06:31 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2018-08-20 12296478m17暂无昵称

    什么时候有针对胃食管结合部腺癌的药物啊?

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=348539, encodeId=dd6834853946, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=093a2086909, createdName=1321f36813m, createdTime=Mon Oct 08 21:43:20 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=340493, encodeId=631e340493a4, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Aug 24 07:51:50 CST 2018, time=2018-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376928, encodeId=5cfe13e6928f6, content=<a href='/topic/show?id=4df06311110' target=_blank style='color:#2F92EE;'>#欧狄沃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63111, encryptionId=4df06311110, topicName=欧狄沃)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62a7397, createdName=charl1234567, createdTime=Wed Aug 22 06:37:00 CST 2018, time=2018-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339773, encodeId=cb95339e73f5, content=得一个癌症拖累两家子人,用家庭的幸福换取癌症的最后生存期限,这样的政府还是不给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:55:27 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339772, encodeId=53d1339e7233, content=这么高的费用居然还好意思说, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa6d2076143, createdName=1331f12a6dm, createdTime=Mon Aug 20 18:53:45 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339757, encodeId=1a6a339e574e, content=还是挺高的啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Mon Aug 20 16:15:32 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339754, encodeId=413b339e54d7, content=什么时候有针对胃食管结合部腺癌的药物啊?, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc742343280, createdName=12296478m17暂无昵称, createdTime=Mon Aug 20 16:11:51 CST 2018, time=2018-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=339753, encodeId=b1af339e53bc, content=一个月近四万 在中国又有多少人能用的起, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=adc92365722, createdName=122e0f42m02暂无昵称, createdTime=Mon Aug 20 16:06:31 CST 2018, time=2018-08-20, status=1, ipAttribution=)]
    2018-08-20 122e0f42m02暂无昵称

    一个月近四万 在中国又有多少人能用的起

    0